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Abstract
Background: The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the toxicity and
biological activity of dioxins and related chemicals. The AhR influences a variety of processes involved in cellular growth and
differentiation, and recent studies have suggested that the AhR is a potential target for immune-mediated diseases.
Methodology/Principal Findings: During a screen for molecules that activate the AhR, leflunomide, an immunomodulatory
drug presently used in the clinic for the treatment of rheumatoid arthritis, was identified as an AhR agonist. We aimed to
determine whether any biological activity of leflunomide could be attributed to a previously unappreciated interaction with
the AhR. The currently established mechanism of action of leflunomide involves its metabolism to A771726, possibly by
cytochrome P450 enzymes, followed by inhibition of de novo pyrimidine biosynthesis by A771726. Our results demonstrate
that leflunomide, but not its metabolite A771726, caused nuclear translocation of AhR into the nucleus and increased
expression of AhR-responsive reporter genes and endogenous AhR target genes in an AhR-dependent manner. In silico
Molecular Docking studies employing AhR ligand binding domain revealed favorable binding energy for leflunomide, but
not for A771726. Further, leflunomide, but not A771726, inhibited in vivo epimorphic regeneration in a zebrafish model of
tissue regeneration in an AhR-dependent manner. However, suppression of lymphocyte proliferation by leflunomide or
A771726 was not dependent on AhR.
Conclusions: These data reveal that leflunomide, an anti-inflammatory drug, is an agonist of the AhR. Our findings link AhR
activation by leflunomide to inhibition of fin regeneration in zebrafish. Identification of alternative AhR agonists is a critical
step in evaluating the AhR as a therapeutic target for the treatment of immune disorders.
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Introduction
The aryl hydrocarbon receptor (AhR) is a member of the Per-
AhR/Arnt-Sim (PAS) family of proteins. The AhR is a cytosolic
transcription factor that, in its latent unliganded state, forms
complexes with HSP90 and XAP2.[1] Upon ligand binding, the
AhR translocates to the nucleus, where it complexes with its
heterodimerization partner, the AhR Nuclear Translocator
(Arnt), to modulate expression of AhR target genes containing
functional xenobiotic response elements (XREs).[1] Activation of
AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is associ-
ated with a number of adverse effects in animals including tumor
promotion and immune suppression.[2] Studies have shown that
the AhR, upon activation by TCDD, inhibits cellular prolifer-
ation by inducing expression of cell cycle inhibitor p27
Kip1.[3]
Interaction of the AhR with retinoblastoma protein has also been
reported. [4,5,6] Further, the AhR has been shown to modulate
cell cycle progression and cellular differentiation independent of
TCDD.[7] In addition, the AhR can also modulate tissue
regeneration pathways in vivo.[8,9] The AhR can induce
m i t o g e n - a c t i v a t e dp r o t e i nk i n a s e sa sw e l la sm o d u l a t ef u n c t i o n
of tyrosine kinases.[10,11] Despite the negative physiological
effects associated with TCDD activation of AhR in vivo,r e c e n t
studies on the AhR suggest that this receptor may play a role in
the control of tumor progression in the absence of exogenous
compounds and further, that modulators of the AhR may be
useful as therapeutics for immune-mediated diseases and
cancer.[12,13,14,15,16]
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compounds in order to identify novel AhR ligands and identified
the anti-rheumatoid arthritis drug leflunomide as a putative AhR
activator. Consistent with this result of our screen, Hu et al
previously reported leflunomide as an AhR activator during a
study evaluating the usefulness of CYP1A1 as a biomarker of AhR
activation.[17] Leflunomide (AravaH) is an immunomodulatory
drug whose primary mechanism of action is attributed to its
metabolite A771726 via inhibition of dihydroorotate dehydroge-
nase, which in turn disrupts pyrimidine biosynthesis and ultimately
inhibits T and B cell proliferation.[18] Potent suppression of the
immune response by TCDD is a well-known AhR-dependent
phenomenon.[15,19,20] Because leflunomide is both an agonist of
the AhR and a known immunosuppressive agent, we aimed to
determine if the biological activity of leflunomide could be
attributed to a previously unappreciated activation of the AhR.
In addition, given that one of the most well known roles of the
AhR is activation of drug metabolizing enzymes upon binding to
xenobiotics,[1] we also investigated leflunomide’s ability to
regulate several genes involved in phase 1 and phase 2 metabolism
in an AhR-dependent manner. This investigation included
CYP1A2, which has been shown previously to facilitate lefluno-
mide conversion to A77176.[21]. Lastly, we investigated in vivo
activation of the AhR and initiation of non-immune related AhR
responses by leflunomide.
Materials and Methods
Cell Culture
Mouse WT Hepa1c1c7 hepatoma cells, mouse Hepa1 B13NBii1
(C4)cells,[22] mousevT{2}cells,[23] mouseHil1.1c2cells,[24] and
human HepG2 hepatoma cells were cultured in DMEM with L-
glutamine (Mediatech Inc., Manassas, VA) supplemented with 10%
FBS (Tissue Culture Biologicals, Tulare, CA) in a humidified 5%
CO2 atmosphere. Mouse WT Hep1c1c7 cells are hereafter referred
to as WT Hepa1, while Hil1.1c2 cells are hereafter referred to as
Hepa1.1 cells. Mouse Hepa1 C4 and VT{2} cells are derivatives of
the WT Hepa1 cell line and were purchased from ATCC. Mouse
Hepa1 C4 cells lack functional Arnt activity due to a point mutation
(GLY326ASP),[25] while vT{2} cells are C4 cells engineered to
stably express a full length Arnt cDNA.[23] Mouse Hepa1.1
cells,[24] were kindly provided by Dr. M.S. Dension (University of
California, Davis, CA, USA). All cell lines were cultured with
100 U/mL penicillin and 100 mg/mL streptomycin (Mediatech
Inc.,Manassas,VA),andweretypicallypassagedeverythreedaysat
a dilution of 1:5. Mouse splenocytes used in ex vivo experiments were
cultured in RPMI 1640 media (Invitrogen, Carlsbad, CA)
supplemented with 10% FBS without antibiotics.
Chemicals and Reagents
Leflunomide and A771726 were purchased from Sigma (St
Louis, MO) and Alexis Biochemicals (Plymouth Meeting, PA),
respectively, and dissolved in DMSO. Fluvoxamine Maleate, a
chemical inhibitor of CYP1A1 and CYP1A2, was purchased from
Tocris Biosciences (Ellisville, MO) and dissolved in DMSO. All
other chemicals, the chemical library, and reagents were
purchased from Sigma (St Louis, MO) unless otherwise noted.
Reporter Gene Constructs
The following constructs were used for reporter gene assays.
Hepa1.1 cells stably express pGudLuc1.1, an expression vector
with a 484-base pair fragment of the promoter region of mouse
cyp1a1 that contains four functional XRE sequences inserted
directly upstream of the mouse mammary tumor virus (MMTV)
viral promoter and firefly luciferase gene.[24] For transient
transfection assays in WT Hepa1, C4, vT{2}, and HepG2 cells,
the XRE-MMTV-Luc expression vector was used. XRE-MMTV-
Luc, hereafter referred to as XRE-Luc, contains a synthetic XRE
oligonucleotide upstream of the MMTV viral promoter.[26]. The
b-galactosidase expression vector, which expresses the b-galacto-
sidase gene under control of a minimal CMV promoter (pCH 110;
Pharmacia), was used for normalization of luciferase activity as
described previously.[27]. PCDNA3.0 (Invitrogen) was used as
carrier DNA for transfection normalization purposes. Reconstitu-
tion of Arnt activity in C4 cells was achieved by transfecting cells
with an expression vector for Arnt.[28]
Reporter Gene Assays
Hepa1.1 cells were plated at a density of 1610
4 cells/well in
100 mL of cell culture media in 96 well plates and grown overnight.
The following day, cells were treated for four hours with vehicle
(DMSO), leflunomide, or A771726; the total concentration of
DMSO did not exceed 0.1% v/v. Following incubation with the
compounds, the media was removed and cells were harvested with
100 mL passive lysis buffer (Promega) for 15 min with mild orbital
shaking. Next, 75 mL of the resulting lysates were collected and
transferred to opaque 96 well plates, where they were assayed well-
by-well for luciferase activity by injection of luciferase assay
substrate (Promega) with a 2 sec mixing time and 15 sec integration
period on a Tropix TR717 microplate luminometer. Data were
expressedasfold inductionsrelative tovehicle(DMSO) treated cells.
For transient transfections, Hepa1, vT{2}, C4, and HepG2 cells
were plated at a density of 0.75610
5 cells/well in 24 well plates
and grown overnight. The following day the cells were transfected
with 600 ng of the XRE-Luc expression vector, 100 ng b-
galactosidase expression vector, and 300 ng PCDNA3.0 as carrier
DNA using Lipofectamine 2000 (Invitrogen, CA) according to the
manufacturer’s recommended protocol. Co-transfection with the
b-galactosidase expression vector was for normalization purposes
as described below. Pertaining specifically to reconstitution of Arnt
activity in C4 cells, which lack functional Arnt activity, cells were
co-transfected with 300 ng Arnt expression vector or with
PCDNA3.0 carrier DNA, thereby keeping the total amount of
DNA transfected equal among experiments.
Approximately 18 hours after transfection the media was
removed and the cells were treated with DMSO, leflunomide, or
A771726 for an additional 18 hours; the total concentration of
DMSO in experiments did not exceed 0.1% v/v. After incubation
with the compounds, cells were lysed essentially as described above
for Hepa1.1 experiments, except that the total lysate volume was
increased to 150 mL, the amount of lysate assayed in the
luminometer was increased to 100 mL, and 10–25 mL of lysate
was used for mouse and human b-galactosidase assays for
transfection normalization, respectively.[29,30,31,32] Briefly, b-
galactosidase activity was determined by incubating a portion of
the cell lysates for approximately 20 minutes with 100 mL b-
galactosidase reaction buffer per well (100 mM sodium phosphate
buffer pH 7.3, 1.25 mM MgCl2, 62.5 mM 2-Mercaptoethanol,
and 1.1 mg/mL O-nitrophenyl-beta-D-galactopyranoside) at
37uC, and reading the absorbance at 405 nm in a spectromax
96-well plate reader. To normalize the data in transient
transfection experiments, raw luciferase values were divided by
their respective b-galactosidase activity. Values are presented as
fold inductions relative to vehicle treated cells.
Chemical Inhibition of CYP1A2
Reporter assays utilizing chemical inhibition of CYP1A2 were
performed as described above for the Hepa1.1 reporter assay, with
Leflunomide Is an AhR Agonist
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(DMSO) or leflunomide, cells were pre-treated for 3 hours with
fluvoxamine at a final concentration of 10 mM. Cells were then
treated for 4 hours with vehicle or leflunomide and luciferase
activity was measured as described above.
Semi-quantitative Polymerase Chain Reaction
For analysis of AhR target gene induction, Hepa1, C4,
VT{2}, or HepG2 cells were plated in 6 well dishes and grown
overnight such that they were 50% confluent at the time of
treatment. Cells were then treated with vehicle (DMSO) and
varying levels of either leflunomide or A771726 for approxi-
mately 18 hours, at which time they were harvested using the
RNeasy kit (Qiagen) according to the manufacture’s recom-
mended protocol. The concentration of RNA lysates were
quantified with a nanodrop spectrophotometer and frozen at
220uC until needed. Reverse Transcriptase PCR analysis was
performed using the Superscript RT III Kit with random
hexamers and a 1 mg RNA Input (Invitrogen, CA). Semi-
quantitative Real Time PCR was performed following cDNA
synthesis exactly as previously described.[33] Primers were
designed to amplify Cytochrome P450 1A1 (CYP1A1), Cyto-
chrome P450 1A2 (CYP1A2), UDP glucuronosyltransferase 1A1
(UGT1A1), NAD(P)H dehydrogenase [quinone 1] (NQO1), and
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which
wa su s e da sac o n t r olf o req ua ll o ading. Thesequences,accession
numbers,andspeciesspecificityfortheprimers usedinthis study
are shown in Table 1. Aliquots of individual PCR reactions at
non-saturating PCR conditions were removed at various cycle
numbers (indicated in figures) and analyzed by agarose gel
electrophoresis on 2.0% TAE gels. Gels were visualized with
ethidium bromide using a GeneGenius digital imaging system
(Syngene).
Immunofluorescence
WT Hepa1 cells (1610
4 cells/well) were plated in 8-well
chamber slides and grown overnight. The following day, cells were
treated with the indicated compounds for either 1 or 3 hours. At
the end of the treatment, cells were processed for immunofluo-
rescence analysis as described previously.[29,30,31,32,33] Briefly,
cells were fixed with 3.7% paraformaldehyde, followed by a 10-
minute incubation with 0.1% Triton X-100. After fixing, cells
were blocked (1% w/v BSA Fraction V) for 1 hour at room
temperature (RT). Primary staining was then performed using an
AhR antibody (Biomol, Plymouth Meeting, PA) diluted 1:800
dilution in blocking medium for 3 hours at RT. After extensive
washing with PBS, cells were stained with a FITC conjugated
goat-anti-rabbit secondary antibody (Southern Biotech, Birming-
ham, AL) at a dilution of 1:600 for 1 hour at RT. Slides were then
washed with PBS three times and coverslippped with Pro-Fade
staining reagent with DAPI (Molecular Probes, Invitrogen). Cells
were imaged with a Zeiss Axiovert 200 inverted microscope
equipped with a camera and Metamorph image capture software.
Molecular Docking Studies
Leflunomide and its metabolite A771726 were docked into a
mouse and human AhR ligand binding domain (LBD) homology
model using ICM software as described previously, and the
binding energy was subsequently calculated.[33]
Zebrafish Care
AB strain (wildtype) embryos were obtained from the Sinnhuber
Aquatic Research Laboratory in the Aquatic Biomedical Models
Facility Core of the Environmental Health Sciences Center,
Oregon State University. Zebrafish were raised using standard
protocols in compliance with Oregon State University animal care
and use protocols. Embryos were incubated at 28uC for all
experiments.
Zebrafish Fin Regeneration Assay
The fin regeneration assays were performed as described
previously.[9] Briefly, 48 hours post fertilization (hpf) embryos
were dechorionated, anesthetized with tricaine (tricaine meth-
anesulfonate; MS-222), placed on a 1% agarose plate, and the
primordial caudal fin was amputated just posterior to the
notochord using a surgical blade. Embryos were allowed to
recover in embryo water approximately 10 minutes followed by a
3-day exposure to vehicle, leflunomide (25 mM), or A771726
(10 mM) diluted in embryo water. Three days post amputation
(dpa) embryos were evaluated for mortality, abnormal develop-
ment, and fin regeneration. Photographs were collected by
placing embryos on agarose plates and using a macro camera
(Nikon Coolpix 5000) attached to a stereomicroscope (Nikon
SMZ1500).
Zebrafish Morpholino Gene Knockdowns
Antisense repression of AhR2 was performed using a translation
start-site targeting morpholino oligonucluotide (MO) (Gene Tools,
Table 1. Primer sequences for RT-PCR experiments.
Gene Accession # Species FP (59-39)R P ( 5 9-39)
GAPDH NM_002046.3 H/M ACCACAGTCCATGCCATCAC
1 TCCACCACCCTGTTGCTGTA1
CYP1A1 NM_009992.3 M CTGGTAACCAACCCTAGG
1 CAGGAAGAGAAAGACCTCC
1
CYP1A2 NM_009993.3 M TGACCGTCCCCAGCTGCC GTGGCCATGCCTGGACGTG
NQO1 NM_008706.5 M GCCATTCTGAAAGGCTGG
1 CGTTTCTTCCATCCTTCCAG
1
UGT1A1 NM_201645.2 M GAACGTGCTCCTGGCCGTG AGCGCCACAGGACCGTCTG
CYP1A1 NM_000499.3 H GTCCCCTTCACCATCCC CAGGAAGAGAAAGACCTCC
CYP1A2 NM_000761.3 H GCCTAGAGCCAGCGGCAACC GCCATCGGCGGTGAGGAACC
NQO1 NM_000903.2 H TCCACCTCAAACGGGCCGG ACCACTGCAGGGGGAACTGG
UGT1A1 NM_000463.2 H TGGCTGAGCATGCTTGGGGC GCCACGATGGGGCTGCAAGG
H: Human M: Mouse, FP: Forward Primer, RP: Reverse Primer.
1Sequences described previously.[33]
doi:10.1371/journal.pone.0013128.t001
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to 3 mM in 16Danieau’s solution (58 mM NaCl, 0.7 mM KCl,
0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5 mM HEPES, pH 7.6) as
described previously.[34] Next, 2 nL of the AhR2 or standard
control MO (Gene Tools) solutions were microinjected into 1–2
cell stage embryos. A fluorescein tag at the 39 end of the MOs was
used to evaluate microinjection efficiency at 24 hpf. Six hpf MO-
injected embryos were exposed to vehicle, leflunomide (10 mM), or
A771726 (10 mM) and incubated for 3 days followed by toxicity
evaluations and immunohistochemistry. A total of 48 hpf embryos
were dechorionated and either directly exposed to DMSO
(vehicle), leflunomide (10 mM), or A771726 (1 mMo r1 0 mM)
diluted in embryo water or had their caudal fin amputated prior to
treatment with the test compounds. Embryos were then incubated
for 3 days followed by morphological evaluation and immunohis-
tochemical staining.
Zebrafish CYP1A Immunohistochemistry
Following exposure to the indicated compounds, embryos
were euthanized with tricaine and fixed overnight in 4%
paraformaldehyde followed by immunostaining of zfCYP1A as
described previously.[9] The primary monoclonal antibody
Figure 1. Induction of AhR-mediated reporter gene activity by leflunomide. (A) Hepa1.1 cells were treated with varying doses of
leflunomide ranging from 0.3 to 30 mM for 4 hours and luciferase activity was measured. Treatment with 1 nM TCDD was included as a positive
control. Leflunomide strongly induced the luciferase reporter gene starting from 1 mM. (B) WT mouse Hepa1 hepatoma or human HepG2 hepatoma
cells (C) were transiently transfected with an XRE-Luc reporter gene and b-galactosidase expression vector as described in the methods section. Cells
were treated with leflunomide or TCDD as indicated for 16 hours and assayed for luciferase activity; Luciferase values are normalized to b-
galactosidase activity. In both WT Hepa1 and HepG2 cells, treatment with 10, 5, or 1 mM significantly increased reporter gene activity, although to a
lesser extent than 1 nM TCDD. (D) HepG2 cells were co-transfected with an Arnt expression vector (300 ng) along with the XRE-Luc reporter gene
(600 ng). A significant increase in the XRE reporter gene activity was observed compared to HEPG2 cells transfected with the XRE reporter construct
alone. Results are the mean 6 SEM of at least three independent experiments. *** p,0.0001, ** p,0.001, * p,0.05 as determined by ANOVA with a
Newman-Keuls multiple comparison post-test.
doi:10.1371/journal.pone.0013128.g001
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Laboratories, Bergen, Norway). The secondary antibody used
was Alexa-546 conjugated goat anti-mouse, 1:1000 (Molecular
Probes, Eugene, OR). Embryos were mounted in 50% gly-
cerol on a glass coverslip and imaged with an Axiovert 200 M
(Zeiss).
Lymphocyte Proliferation Assay
C57BL/6J (B6) mice and B6.129-AhRtm1Bra/J (AhR 2/2)
mice (purchased from The Jackson Laboratory) were bred and
maintained in our specific pathogen-free animal facility at
Oregon State University. All animal procedures were approved
by the Institutional Animal Care and Use Committee. Spleens of
AhR +/+ and AhR 2/2 mice were removed and whole
splenocyte suspensions were prepared. Cells were then labeled
with carboxyfluorescein succinimidyl ester (CFSE) [35] and
cultured with 250 ng/mL anti-CD3 and 10 mg/mL LPS in the
presence of 0, 5, 10 or 50 mM leflunomide or 10 or 50 mM
A771726. After 72 hours, the cells were harvested and stained
with fluorochrome-labeled antibodies to CD4 and CD8 and
B220 (BD Pharmingen) for flow cytometric analysis. Subset-
specific cell division was measured based on the two-fold dilution
of CFSE fluorescencethat occurswith eachround of cell division.
Flow analysis was performed using a Beckman Coulter FC500
flow cytometer and analyzed with WinList software (Verity
Software House).
Statistical Analysis
Reporter gene studies and leflunomide proliferation assays in
AhR +/+ or AhR 2/2 splenocytes were analyzed by one and
two-way ANOVA, respectively. Values of p,0.05 were consid-
ered statistically significant.
Results
Leflunomide Induces AhR-Response Element-Containing
Reporter Genes
Following the identification of leflunomide as a putative AhR
ligand from our small molecule screening, we set out to further
characterize the compound’s ability to activate AhR transcrip-
tion. To this end, we performed reporter gene assays to
investigate the dose-dependent activation of the AhR by
leflunomide. We first used a mouse hepatoma cell line stably
expressing an AhR responsive luciferase reporter gene
(Hepa1.1) [24] and found that leflunomide activated AhR
transcription starting from 1 mM in a dose-dependent manner
(Figure 1A), which was in accordance with our screening data
and other published studies.[17] To further assess leflunomide
Figure 2. Activation of the AhR target genes by leflunomide. Hepa1 and HepG2 cells were treated with vehicle (V, 0.1% DMSO), TCDD (T,
1 nM), or leflunomide (L20, 20 mM; L10, 10 mM; L1, 1 mM) for 18 hours. RNA was isolated and semi quantitative RT-PCR was performed for the AhR
target genes Cytochrome P450 1A1 (CYP1A1), Cytochrome P450 1A2 (CYP1A2), UDP glucuronosyltransferase 1A1 (UGT1A1), and NAD(P)H
dehydrogenase [quinone 1] (NQO1), as described in the methods section. Expression analysis of GAPDH (Glyceraldehyde-3-phosphate
dehydrogenase) was performed as a control. Cycle numbers during which PCR reactions were sampled are indicated. PCR products were visualized
on a 2% TAE agarose gel stained with ethidium bromide. Leflunomide activated the selected panel of AhR target genes in WT Hepa1 (A) and HepG2
cells (B).
doi:10.1371/journal.pone.0013128.g002
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13128Figure 3. Activation of AhR target genes by leflunomide requires Arnt. (A) Induction of the AhR target genes CYP1A1, UGT1A1, and NQO1
was performed as in figure 2. Vehicle (V, 0.1% DMSO), TCDD (T, 1 nM), leflunomide (L20, 20 mM; L10, 10 mM). GAPDH expression was used as a control.
PCR cycle numbers are indicated. Target gene induction in Hepa1 vT{2} cells expressing a functional Arnt protein was similar as to that seen with WT
Hepa1 cells. CYP1A1 and NQO1 were not induced by leflunomide in Hepa1 C4 cells that do not express a functional Arnt protein. (B–C) XRE-Luc
reporter gene assays in Hepa1 vT{2} and C4 cells. Cells were transfected and treated with leflunomide or controls (VEH, Vehicle, 0.1% v/v DMSO;
TCDD, 1 nM; and LEF, leflunomide,10 mM) as described in the methods section. (B) Consistent with semi quantitative RT-PCR analysis, TCDD and
leflunomide induced expression of the XRE-Luc reporter gene in Hepa1 vT{2} cells. (C) Treatment with TCDD or leflunomide failed to activate the XRE-
Leflunomide Is an AhR Agonist
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and mouse WT Hepa1 hepatoma cells with a luciferase reporter
gene expression vector under control of a promoter containing
xenobiotic response elements (XRE-Luc). Consistent with our
observations in Hepa1.1 cells, we observed activation of AhR-
m e d i a t e dt r a n s c r i p t i o ni nb o t hH e p a 1( F i g u r e1 B ) ,a n dH e p G 2
(Figure 1C) cell lines. When we transiently expressed additional
levels of Arnt in HepG2 cells (Figure 1D), induction of the XRE
reporter increased significantly.
Activation of AhR Target Genes by Leflunomide
After confirming leflunomide’s ability to induce AhR-responsive
reporter genes, we next evaluated leflunomide’s ability to
modulate expression of several known endogenous AhR target
Luc reporter in the Hepa1 C4 cells. However, transient co-expression of Arnt rescued XRE-Luc reporter gene induction. Reporter gene assays are the
mean 6 SEM of three independent experiments.
doi:10.1371/journal.pone.0013128.g003
Figure 4. Leflunomide, but not its active metabolite, A771726, activates the AhR. (A) Structures of leflunomide (left) and its metabolite
A771726 (right). (B–C) Reporter gene assays were conducted in Hepa1.1 cells or in HepG2 cells transiently transfected with XRE-Luc reporter gene.
Results are the mean 6 SEM of at least three independent experiments, each of which consisted of at least three biological replicates. ***: p,0.001
compared with vehicle treatment and p,0.05 compared with corresponding dose of A771726. (D) To confirm the observations of the reporter gene
assays, we performed semi quantitative RT-PCR in WT Hepa1 cells for CYP1A1 with total RNA isolated from cells treated with vehicle (0.1% DMSO),
leflunomide (L, 20 mM) or A771726 (M, 20 mM) as described in Figure 2. GAPDH was included as a control. Consistent with reporter gene assays,
A771726 failed to activate CYP1A1 beyond that of vehicle treatment, while leflunomide induced strong CYP1A1 expression. (E) Cellular localization of
AhR was analyzed by immunofluorescence of Hepa1 cells treated with TCDD, leflunomide, or A771726 for 1 or 3 hours. The FITC (green) channel
represents AhR staining, while DAPI (blue) represents the nucleus. The AhR translocated to the nucleus following treatment with both TCDD and
leflunomide, while it remained in the cytosol following treatment with A771726. (F) M2 is the major tautomeric form of A771726. Molecular docking
of M2 and leflunomide in the homology models of mouse (G) and human (H) AhR ligand binding domain reveal favorable energetic and docking for
leflunomide but not M2.
doi:10.1371/journal.pone.0013128.g004
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evaluated CYP1A1, CYP1A2, NQO1, and UGT1A1 expression
with increasing concentrations of leflunomide. As shown in
Figure 2A, leflunomide exposure strongly induced the transcrip-
tion of CYP1A1, CYP1A2, and NQO1 similar to the maximal
expression produced by 1 nM TCDD exposure. In addition,
despite a significant basal expression of UGT1A1 in WT Hepa1
cells, both leflunomide and TCDD modestly upregulated
UGT1A1. We also evaluated CYP1A1, CYP1A2, NQO1, and
UGT1A1 expression following leflunomide exposure in HepG2
human hepatoma cells. Consistent with the results obtained from
the Hepa1 cells, leflunomide activated all of the AhR target genes
in a dose-dependent manner in HepG2 cells. Together, these data
indicate that leflunomide increases expression of several AhR
target genes involved in drug metabolism in both human and
mouse cells.
Activation of AhR Target Genes by Leflunomide Requires
the AhR Heterodimerization Partner Arnt
Given that the structure of leflunomide differs significantly
from that of the classical ligand, TCDD, we wanted to confirm
that its ability to activate transcription of AhR target genes was
dependent on the presence of a functional Arnt protein, which
would indicate that leflunomide activates AhR signaling through
the classical pathway. To this end, we used the C4 mutant cell
line, which has non-functional Arnt activity (Arnt G326D) [25],
and Hepa1 VT{2} cells, which have restored Arnt activity due
to stable re-expression of wildtype Arnt.[23] We performed
semi-quantitative PCR to evaluate target gene induction in the
two Hepa1 derivative cell lines following treatment with
leflunomide (Figure 3A). The AhR target genes CYP1A1,
UGT1A1, and NQO1 were induced in the Arnt transcription
proficient cell line following exposure to leflunomide; however,
induction of NQO1 was considerably weaker. Neither CYP1A1
nor NQO1 was induced by leflunomide in the Hepa1 C4 cell
line, whereas basal UGT1A1 expression was not altered.
Furthermore, leflunomide activated XRE-Luc reporter gene
activity in Hepa1 vT{2} cells in a dose-dependent manner, with
a maximal induction comparable to that of TCDD (Figure 3B),
while neither TCDD nor leflunomide increased reporter gene
activity in the Arnt deficient Hepa1 C4 line (Figure 3C). To
verify the results observed in vT{2} cells, C4 cells were also
transiently co-transfected with an expression vector for Arnt,
which rescued induction of the XRE-Luc reporter by both
TCDD and leflunomide (Figure 3C).
Leflunomide, but not its Biologically Active Metabolite,
A771726, Activates the AhR
Previously, an in vitro metabolism study on isoxazole ring scission
found that leflunomide may be metabolized via a cytochrome
Figure 5. Leflunomide induces aryl hydrocarbon receptor dependent expression of CYP1A1 in zebrafish. (A) One-cell stage wildtype
embryos were injected with a control morpholino or AhR2 morpholino. At 6 hpf, the zebrafish were exposed to 10 mM leflunomide for 3 days.
Immunohistochemistry for CYP1A, a known AhR2 target gene in zebrafish, demonstrated that leflunomide induces CYP1A expression in an AhR2
dependent manner. (B) Exposure of zebrafish to A771726 at doses of either 1 or 10 mM did not increase CYP1A expression.
doi:10.1371/journal.pone.0013128.g005
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its active metabolite, A771726.[21] Given the significant structural
change incurred during the metabolism of leflunomide to
A777176 (Figure 4A), we were interested to determine whether
the metabolite could also activate the AhR. To this end, we
performed reporter gene assay with both leflunomide and
A771726 in Hepa1.1 cells (Figure 4B) and HepG2 cells
(Figure 4C). While leflunomide activated the reporter gene in a
concentration-dependent manner, A771726 failed to significantly
induce the AhR-dependent reporter gene in both the cell lines. We
also evaluated the induction of CYP1A1 by leflunomide and
A771726 using semi-quantitative RT-PCR (Figure 4D). Consistent
with the reporter gene data, A771726 failed to induce CYP1A1
expression beyond that of vehicle treatment, while leflunomide
strongly induced CYP1A1 expression, consistent with earlier
observations.
To further confirm our observation that A771726 is not an AhR
agonist, we evaluated the ability of both leflunomide and A771726
to facilitate AhR translocation from the cytosol to the nucleus
(Figure 4E). After treatment for 1 and 3 hours, both TCDD and
leflunomide strongly promoted AhR nuclear localization, while
A771726 did not. Together, these data indicate that leflunomide
but not its metabolite, A771726, is a ligand of the AhR.
Molecular Docking of Leflunomide and A771726
We were next interested in determining if there is a structural
explanation for the observed disparity between the AhR activation
by leflunomide, but not its metabolite. To this end, leflunomide
and its metabolite A771726 (Figure 4A) were docked into the
mouse and human AhR-LBD homology model as previously
described. [33] For the primary metabolite, A771726, the most
predominant tautomeric form in solution, M2 [21], was
considered in the study (Figure 4F). Both compounds docked into
the binding pocket, but produced distinct binding energetics.
Specifically, leflunomide established two hydrogen bond (HB)
interactions between the nitrogen atom of the isoxazole ring of the
ligand and the OH of the side chain of Thr 289/283 and between
the amide NH of the ligand and the carbonyl CO of the side chain
of Gln 383/377 (Figure 4G) with a predicted binding energy of
22.65 kcal/mol (human) and 22.84 kcal/mol (mouse). Converse-
ly, A771726 established only a single HB interaction between the
nitrogen of the CN of the compound and the OH of the side chain
of Thr 289/283 (Figure 4H) but with a high unfavorable
(+77.5 kcal/mol (human); +40.48 kcal/mol (mouse)) binding
energy. This was due to the clash in the binding pocket between
the carbonyl oxygen CO of the amide group of the compound and
the side chain of His 291/285 (Figure 4G). Thus, the observed
Figure 6. Leflunomide acts through the AhR to inhibit regeneration in an AhR-dependent manner. Amputation of the caudal zebrafish
fin is a well-established model used to study tissue regeneration; TCDD is known to inhibit this regeneration process. To investigate whether
leflunomide behaves like TCDD to inhibit epimorphic regeneration through the AhR, one-cell stage embryos were injected with a control or AhR2
morpholino, and the caudal fin was amputated at 48 hpf, followed by immediate exposure to vehicle or 25 mM leflunomide. (A) After 3 days, images
of the fins were taken with brightfield microscopy. In addition, immunohistochemistry for CYP1A confirmed that leflunomide activated AhR2 (dotted
line indicates the plane of amputation). (B) Although A771726 did not appear to activate the AhR in vivo or in our cell culture models, we investigated
whether the compound could also inhibit fin regeneration, as inhibition of cell growth via disruption of de novo pyrimidine biosynthesis inhibition is a
well-characterized endpoint of A771726. Amputated zebrafish were exposed to vehicle or 10 mM A771726. Exposure to 10 mM A771726 did not
influence the regenerative process.
doi:10.1371/journal.pone.0013128.g006
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PLoS ONE | www.plosone.org 10 October 2010 | Volume 5 | Issue 10 | e13128AhR agonistic activity of leflunomide as well as inactivity of
A771726 could be explained by in silico molecular docking.
Leflunomide, but not its Active Metabolite, A771726,
Induces AhR-dependent CYP1A Expression in vivo
Following characterization of AhR activation by leflunomide in
mouse and human hepatoma cells, we evaluated the functional
consequences of AhR activation in vivo using the embryonic
zebrafish model.[9] We first evaluated whether leflunomide
exposure induced AhR target gene CYP1A in vivo. Zebrafish
embryos were waterborne exposed to 10 mM leflunomide from
6 hpf to 120 hpf, after which CYP1A expression was evaluated by
immunohistochemistry. In the absence of exogenous ligand,
CYP1A expression was undetectable, and leflunomide exposure
strongly induced CYP1A expression throughout the larval
vasculature. Zebrafish have three AhR isoforms and AhR2 was
shown to be the dominant isoform that regulates CYP1A in
response to TCDD treatment.[8] To determine if the leflunomide-
mediated CYP1A induction was AhR2-dependent, we used AhR2
morpholinos to repress AhR2 expression. While leflunomide
induced strong CYP1A expression in control morphants
(Figure 5A), CYP1A expression was markedly reduced in the
AhR2 morphants, indicating that the induction was AhR2-
dependent. However, exposure to A771726 did not increase
CYP1A expression (Figure 5B). Taken together, these data
indicate that leflunomide, but not its metabolite, activates the
AhR in vivo.
Leflunomide Blocks AhR2-Dependent Fin Regeneration
Activation of the AhR modulates cell differentiation and
proliferationinavariety ofcontexts.[3,4,36] Wepreviously developed
zebrafish fin regeneration models to identify the mechanism by which
AhR alters signal transduction pathways in vivo.I n a p p r o p r i a t e
activation of the AhR by TCDD completely abrogates tissue
regeneration[8] via an AhR2-dependent mechanism.[9] AhR blocks
the regenerative response by cross-talk with the b-catenin and Wnt
signaling pathways.[37] To determine if leflunomide exposure would
block fin regeneration via AhR2 activation, we generated AhR2
morphants, amputated the caudal fins at 48 hpf, and immediately
exposed them to vehicle or leflunomide for 3 days, after which the
extent of tissue regeneration was assessed by standard light
microcopy. Leflunomide exposure completely blocked fin regenera-
tion in the control morphants, but regeneration was restored in the
AhR2 morphants (Figure 6A). Immunohistochemistry revealed that
CYP1A was highly expressed in the leflunomide-exposed control
morphants and CYP1A expression was significantly reduced in
leflunomide-exposed AhR2 morphants (Figure 6A). These results
demonstrate that leflunomide behaves as an AhR ligand in vivo.I n
contrast, A771726 was unable to activate the AhR and did not
impact fin regeneration (Figure 6B). Since A771726 did not block
regeneration, this suggests that the regenerative process is not
responsive to dihydroorotate dehydrogenase inhibition, suggesting
that the observed effects of leflunomide in zebrafish are independent
of its metabolite, A771726.
The AhR is not required for the anti-proliferative effects
of leflunomide in primary T cells
Given the observation that leflunomide was able to elicit an
AhR-dependent inhibition of regeneration in the zebrafish
model, we next asked whether AhR is involved in the
immunosuppressive action of leflunomide or A771726 in CD4
+
or CD8
+ Tc e l l sf r o mA h R2/2 and AhR +/+ backgrounds
(Figure 7A). In order to evaluate the effects of leflunomide and
A771726 on cell proliferation, we confirmed that leflunomide or
A771726 did not alter the viability of the analyzed cell
populations compared with vehicle treatment (Figure 7B). Viable
CD4
+ or CD8
+ T cells (Figure 7B) from AhR +/+ or AhR 2/2
mice were then analyzed as a function of CFSE staining to
determine the number of cellular divisions that had taken place.
The growth inhibitory actions of both leflunomide and A771726
in CD4
+ and CD8
+ T-cells were readily apparent when
compared to vehicle treated cells. Leflunomide potently reduced
the number of cell divisions in both CD4
+ and CD8
+ T-cells
(Figures 7C–D). Specifically, leflunomide at 5 mM suppressed the
number of cells undergoing three or more divisions, whereas
leflunomide at 50 mM suppressed proliferation beyond one
d i v i s i o n .( F i g u r e s7 C – D ) .H o w e v e r ,n od i f f e r e n c ew a so b s e r v e d
in the growth inhibition patterns by leflunomide in cells from
AhR positive or null mice (Figures 7C–D). A771726 was also able
to inhibit proliferation of CD4
+ or CD8
+ Tc e l l s ,b u tn o
difference was observed between AhR +/+ and AhR 2/2 cells.
In addition, the degree of inhibition by A771726 was similar to
that of leflunomide Figures 7E–F). Together, these data suggest
that neither the metabolism of leflunomide to A771726 nor their
respective anti-proliferative effects could be linked to AhR
activation in mouse splenocytes.
Inhibition of CYP1A2 increases leflunomide-induced AhR
reporter gene activity
As shown in Figure 4, cytochrome P450-mediated isoxazole ring
scission leading to the conversion of leflunomide to A771726
results in a loss of ability to activate the AhR. To further study the
metabolism of leflunomide to A771726, and specifically the role of
CYP1A2 (and to a lesser extent CYP1A1, due to its genetic
similarity to CYP1A2) in this metabolism, we utilized fluvoxamine,
a chemical inhibitor of CYP1A2 (as well as CYP1A1). [38] First,
we identified the lowest dose of leflunomide that can activate AhR
in Hepa1.1 cells (Figure 8A). Next, we pre-treated the cells with
fluvoxamine before treating them with a limiting leflunomide
concentration and assessed luciferase activity. As would be
expected for a role for CYP1A1/2 in the metabolism of
leflunomide to A771726,[21] we observed a modest, but
Figure 7. The AhR is not required for the suppression of murine T-cell proliferation by leflunomide. Spleens of AhR +/+ and AhR 2/2
mice (A, Western blot) were removed and whole murine splenocytes were labeled with Carboxy-Fluoroscein-Diacetate Succinimidyl-Ester (CFSE) and
stimulated to proliferate in vitro with anti-CD3 and LPS treatment in the absence or presence of vehicle and different doses of leflunomide or
A771726. After 3 days, cells were harvested and stained for CD4 or CD8. (B) Viable cells were gated and CD4 and CD8 positive cell populations were
then analyzed using single parameter (CFSE) histograms to evaluate cellular divisions based on CFSE staining. Cellular viability was not affected by
either leflunomide or A771726 at the concentrations used. (C) Dose-dependent inhibition of cellular proliferation by leflunomide in CD4
+ cells is not
dependent upon the AhR. (D) Dose-dependent inhibition of cellular proliferation by leflunomide in CD8
+ cells is not dependent upon the AhR. (E–F)
A771726-induced inhibition of CD4
+ or CD8
+ proliferation is similar between AhR +/+ and AhR 2/2 cells. AhR 2/2 cells, black bars; AhR +/+ cells,
white bars. Results are the mean from two independent experiments. Two-way ANOVA for both CD4
+ and CD8
+ assays did not reveal any statistically
significant differences between cell divisions in AhR +/+ and AhR 2/2 cells whereas the effect of leflunomide on cell division compared to vehicle
treatment was highly significant in both cases (p,0.0001).
doi:10.1371/journal.pone.0013128.g007
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luciferase reporter gene activity upon chemical inhibition of
CYP1A1/2 (Figure 8B).
Discussion
The AhR is gaining interest as a potential therapeutic target for
the treatment of immune-mediated diseases.[12,15,39] While the
AhR is commonly associated with TCDD toxicity, it is
increasingly clear that there are aspects of AhR activation that
can be beneficial. Activation of AhR activity by TCDD has been
shown to suppress autoimmune disease development, including
that of type 1 diabetes and Experimental Autoimmune Enceph-
alomyelitis.[15,40,41,42,43,44] However, clinical use of TCDD is
unlikely due to its history as an environmental toxicant. Therefore,
we searched for AhR ligands that trigger the beneficial aspects of
the AhR without unwanted side-effects such as those seen with
TCDD. Pharmaceuticals already in use in the clinic are ideal
candidates to screen for such selective AhR activation, as many
potential toxicity issues have already been addressed. In the
present study, we coupled the identification of hits from a small
molecule screen for novel AhR ligands with a rapid in vivo model
for testing the consequences of AhR activation.[9]
Mimicking the beneficial effects of TCDD (i.e. immunosup-
pression) with alternative non-toxic AhR ligands may prove to be a
useful therapeutic strategy for immune-mediated diseases. In our
search for alternative AhR ligands, we found the anti-inflamma-
tory drug, leflunomide, activated the AhR, resulting in induction
of several known AhR target genes. Interestingly, we also observed
that leflunomide induced CYP1A2 expression. Further, consistent
with the observation that CYP1A2 can facilitate metabolism of
leflunomide to A771726 in vitro,[21] we found that chemical
inhibition of CYP1A2 enhanced leflunomide-induced AhR
reporter gene activity. Induction of drug metabolizing enzymes
(DMEs), following exposure to xenobiotics has been established as
a major activity of the AhR.[1] In light of this fact, our results
suggest a possible role for the AhR in mediating the conversion of
leflunomide to A771726. However, other DMEs have also been
shown to facilitate conversion of leflunomide to A771726.[21,45]
Identification of novel AhR ligands and subsequent analysis of
their effects on AhR biology is important for developing the AhR
as a clinically relevant therapeutic target. Indeed, given that
leflunomide can activate the AhR in vivo and produce an AhR-
dependent effect on tissue regeneration, future studies may
reveal useful therapeutic applications of leflunomide or related
compounds. The AhR’s ability to regulate cell proliferation
may also be exploited for therapeutic purposes including cancer
treatment.
In conclusion, we found that leflunomide, but not its metabolite
A771726,isanagonistofthe AhR.Leflunomidewasabletoactivate
the AhR in vivo, where it was able to mediate AhR-dependent effects
on tissue regeneration. As leflunomide is a drug currently in use in
the clinic and is an agonist of the AhR, our results support the
feasibility of developing AhR-targeted therapeutics.
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Figure 8. Inhibition of CYP1A2 by fluvoxamine increases AhR-
mediated reporter gene activity. A) Identificationoflimiting doses of
leflunomide capable of activating the AhR. Hepa1.1 cells were treated for
4 hours with varying doses of leflunomide in order to identify
concentrations necessary for minimal activation of reporter gene activity.
Leflunomide at 0.5 mM (dashed box) resulted in an approximately 2-fold
induction of reporter gene and was selected for further analysis with the
CYP1A2 inhibitor fluvoxamine. B) The CYP1A2 inhibitor fluvoxamine
increases leflunomide-induced reporter gene activity in Hepa1.1 cells.
Hepa1.1 cells were pre-treated with fluvoxamine for 3 hours and then
dosed with 0.5 mM leflunomide for an additional 4 hours. Leflunomide-
mediated reporter gene activity was enhanced by pre-treatment with
fluvoxamine compared with vehicle treated cells and fluvoxamine-only
treated cells. Results are the mean 6 SEM of three independent
experiments, each with at least three biological replicates. * p,0.05
relative to vehicle treatment, ** p,0.001 relative to both vehicle
treatment and vehicle treated cells pre-treated with fluvoxamine.
doi:10.1371/journal.pone.0013128.g008
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